Trial Profile
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWIN II
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Trastuzumab emtansine (Primary) ; Vemurafenib (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DARWIN II
- 28 Nov 2023 Planned End Date changed from 1 Nov 2025 to 1 May 2026.
- 28 Nov 2023 Planned primary completion date changed from 1 Nov 2024 to 1 May 2026.
- 28 Nov 2023 Status changed from recruiting to active, no longer recruiting.